Elevated serum OxLDL is associated with progression of type 2 Diabetes Mellitus to diabetic retinopathy. (September 2019)

• Record Type: Journal Article
• Authors: Kuppan, Kaviarasan; Mohanlal, Jithu; Mohammad, Arif Mulla; Babu, Kannadasan Anand; Sen, Parveen; Undurti, Narasimha Das; Natarajan, Viswanathan; Narayanasamy, Angayarkanni
• Is Part Of: Experimental eye research. Volume 186(2019)
• Publication Date: 2019-09
• Subjects: oxLDL -- AGE -- PON -- MDA -- T2DM -- Diabetic retinopathy; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2019.05.008
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Hyperlipidemia is associated with the progression of diabetic retinopathy (DR). Paraoxonase 1 (PON1), an esterase is known to prevent systemic LDL oxidation. This study assessed if serum oxLDL is associated with the progression of Type 2 DM to DR. This study is part of a three-year hospital based prospective study where 87 subjects were recruited. This included T2DM without DR (n = 22); Non-Proliferative (NPDR) (n = 21) and Proliferative DR (PDR) (n = 22) along with age/sex matched controls (n = 22). Serum oxLDL-Ab was estimated by ELISA. Serum PON esterase activity and plasma Malondialdehyde (MDA) level were estimated by spectrophotometry and the serum Advanced Glycation End products (AGE) level by spectroflourimetry. The systemic levels of oxLDL, AGE and MDA were increased with the progression of T2DM without DR to DR as seen by ANOVA (P < 0.05). Serum oxLDL-Ab levels showed a positive correlation to total cholesterol (P = 0.04) as evaluated in the DR group. Statin intake was found to lower PON esterase activity (P < 0.05). Based on this pilot study, it is proposed that elevated serum oxLDL should be validated in larger cohort studies to ensure it could be potential risk factor for the progression of T2DM to DR. Highlights: This study highlights the relevance of oxLDL measured as oxLDL-Ab as a prognostic marker for the progression of T2DM to DR.